Brain structural correlates of an impending initial major depressive episode.

IF 6.6 1区 医学 Q1 NEUROSCIENCES
Anna Kraus, Katharina Dohm, Tiana Borgers, Janik Goltermann, Dominik Grotegerd, Alexandra Winter, Katharina Thiel, Kira Flinkenflügel, Navid Schürmeyer, Tim Hahn, Simon Langer, Tilo Kircher, Igor Nenadić, Benjamin Straube, Hamidreza Jamalabadi, Nina Alexander, Andreas Jansen, Frederike Stein, Katharina Brosch, Paula Usemann, Lea Teutenberg, Florian Thomas-Odenthal, Susanne Meinert, Udo Dannlowski
{"title":"Brain structural correlates of an impending initial major depressive episode.","authors":"Anna Kraus, Katharina Dohm, Tiana Borgers, Janik Goltermann, Dominik Grotegerd, Alexandra Winter, Katharina Thiel, Kira Flinkenflügel, Navid Schürmeyer, Tim Hahn, Simon Langer, Tilo Kircher, Igor Nenadić, Benjamin Straube, Hamidreza Jamalabadi, Nina Alexander, Andreas Jansen, Frederike Stein, Katharina Brosch, Paula Usemann, Lea Teutenberg, Florian Thomas-Odenthal, Susanne Meinert, Udo Dannlowski","doi":"10.1038/s41386-025-02075-6","DOIUrl":null,"url":null,"abstract":"<p><p>Neuroimaging research has yet to elucidate whether reported gray matter volume (GMV) alterations in major depressive disorder (MDD) exist already before the onset of the first episode. Recruitment of presently healthy individuals with a subsequent transition to MDD (converters) is extremely challenging but crucial to gain insights into neurobiological vulnerability. Hence, we compared converters to patients with MDD and sustained healthy controls (HC) to distinguish pre-existing neurobiological markers from those emerging later in the course of depression. Combining two clinical cohorts (n = 1709), voxel-based morphometry was utilized to analyze GMV of n = 45 converters, n = 748 patients with MDD, and n = 916 HC in a region-of-interest approach and exploratory whole-brain. By contrasting the subgroups and considering both remission state and reported recurrence at a 2-year clinical follow-up, we stepwise disentangled effects of (1) vulnerability, (2) the acute depressive state, and (3) an initial vs. a recurrent episode. Analyses revealed higher amygdala GMV in converters relative to HC (p<sub>tfce-FWE</sub> = 0.037, d = 0.447) and patients (p<sub>tfce-FWE</sub> = 0.005, d = 0.508), remaining significant when compared to remitted patients with imminent recurrence. Lower GMV in the dorsolateral prefrontal cortex (p<sub>tfce-FWE</sub> < 0.001, d = 0.188) and insula (p<sub>tfce-FWE</sub> = 0.010, d = 0.186) emerged in patients relative to HC but not to converters, driven by patients with acute MDD. By examining one of the largest available converter samples in psychiatric neuroimaging, this study allowed a first determination of neural markers for an impending initial depressive episode. Our findings suggest a temporary vulnerability, which in combination with other common risk factors might facilitate prediction and in turn improve prevention of depression.</p>","PeriodicalId":19143,"journal":{"name":"Neuropsychopharmacology","volume":" ","pages":""},"PeriodicalIF":6.6000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuropsychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41386-025-02075-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
引用次数: 0

Abstract

Neuroimaging research has yet to elucidate whether reported gray matter volume (GMV) alterations in major depressive disorder (MDD) exist already before the onset of the first episode. Recruitment of presently healthy individuals with a subsequent transition to MDD (converters) is extremely challenging but crucial to gain insights into neurobiological vulnerability. Hence, we compared converters to patients with MDD and sustained healthy controls (HC) to distinguish pre-existing neurobiological markers from those emerging later in the course of depression. Combining two clinical cohorts (n = 1709), voxel-based morphometry was utilized to analyze GMV of n = 45 converters, n = 748 patients with MDD, and n = 916 HC in a region-of-interest approach and exploratory whole-brain. By contrasting the subgroups and considering both remission state and reported recurrence at a 2-year clinical follow-up, we stepwise disentangled effects of (1) vulnerability, (2) the acute depressive state, and (3) an initial vs. a recurrent episode. Analyses revealed higher amygdala GMV in converters relative to HC (ptfce-FWE = 0.037, d = 0.447) and patients (ptfce-FWE = 0.005, d = 0.508), remaining significant when compared to remitted patients with imminent recurrence. Lower GMV in the dorsolateral prefrontal cortex (ptfce-FWE < 0.001, d = 0.188) and insula (ptfce-FWE = 0.010, d = 0.186) emerged in patients relative to HC but not to converters, driven by patients with acute MDD. By examining one of the largest available converter samples in psychiatric neuroimaging, this study allowed a first determination of neural markers for an impending initial depressive episode. Our findings suggest a temporary vulnerability, which in combination with other common risk factors might facilitate prediction and in turn improve prevention of depression.

大脑结构与即将到来的初始重度抑郁发作的相关性。
神经影像学研究尚未阐明重度抑郁症(MDD)中所报道的灰质体积(GMV)改变是否在首次发作前就已经存在。招募目前健康的个体随后过渡到重度抑郁症(转换者)是极具挑战性的,但对于深入了解神经生物学脆弱性至关重要。因此,我们将转换者与重度抑郁症患者和持续健康对照组(HC)进行比较,以区分先前存在的神经生物学标志物与抑郁症病程后期出现的神经生物学标志物。结合两个临床队列(n = 1709),利用基于体素的形态测定法分析n = 45名转换者、n = 748名重度抑郁症患者和n = 916名HC患者的GMV,采用感兴趣区域法和探索性全脑法。通过对比亚组,并考虑缓解状态和2年临床随访中报告的复发,我们逐步理清了(1)易感性,(2)急性抑郁状态,(3)初次发作与复发发作的影响。分析显示,相对于HC (ptfce-FWE = 0.037, d = 0.447)和患者(ptfce-FWE = 0.005, d = 0.508),转换者的杏仁核GMV更高,与即将复发的缓解患者相比,仍然具有显著性。在急性重度抑郁症患者的驱动下,相对于HC患者,背外侧前额叶皮层GMV较低(ptfce-FWE = 0.010, d = 0.186),而非转换者。通过检查精神病学神经影像学中最大的可用转换样本之一,本研究首次确定了即将发生的初始抑郁发作的神经标志物。我们的研究结果表明,暂时的脆弱性与其他常见的风险因素相结合,可能有助于预测,进而改善抑郁症的预防。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Neuropsychopharmacology
Neuropsychopharmacology 医学-精神病学
CiteScore
15.00
自引率
2.60%
发文量
240
审稿时长
2 months
期刊介绍: Neuropsychopharmacology is a reputable international scientific journal that serves as the official publication of the American College of Neuropsychopharmacology (ACNP). The journal's primary focus is on research that enhances our knowledge of the brain and behavior, with a particular emphasis on the molecular, cellular, physiological, and psychological aspects of substances that affect the central nervous system (CNS). It also aims to identify new molecular targets for the development of future drugs. The journal prioritizes original research reports, but it also welcomes mini-reviews and perspectives, which are often solicited by the editorial office. These types of articles provide valuable insights and syntheses of current research trends and future directions in the field of neuroscience and pharmacology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信